Blue background featuring a collage of photos from research participants. Text in the image reads "a message to our TrialNet family" and "celebrating 2023"
Media Release
Read more
Celebrating a New Era in Type 1 Diabetes Research - A Message from TrialNet Chair Kevan C. Herold, MD
TrialNet Chair Kevan C. Herold, MD, Yale University, reflects on key accomplishments of the past year and shares direction for 2024 and beyond.
Dear TrialNet family,
As we start the new year, I want to take time to recognize TrialNet’s major achievements in 2023 and share our direction for advancing type 1 diabetes (T1D) research in the year ahead.
Orlando Brown, Jr. speaks to reporters in front of a blue JDRF backdrop with orange and white ballons
Participant Spotlight
Read more
NFL Super Bowl Champion Orlando Brown, Jr. hosts JDRF event in Cincinnati – encourages T1D family members to get screened, help advance science
Photo courtesy of JDRF Southern & Central Ohio Chapter
During what proved to be an unforgettable celebration by the JDRF community in Cincinnati, NFL Super Bowl Champion and Bengals offensive lineman Orlando Brown, Jr. encouraged relatives of people with type 1 diabetes (T1D) to get screened by TrialNet to help advance research.
A portrait of research participant Amber wearing a gray-blue sweater and standing beside a brick wall
Participant Spotlight
Read more
Immunotherapy proven to slow T1D progression in people newly diagnosed now being tested for prevention
Amber Van Den Heuvel received low-dose anti-thymocyte globulin (ATG) in 2015 as a participant in a TrialNet clinical study for people newly diagnosed with type 1 diabetes (T1D). Five years later, she still had beta cell function. Today, at age 26, Amber is encouraging people at high risk for T1D to consider participating in a TrialNet prevention study using the same therapy.
